{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T06:17:25Z","timestamp":1751609845894,"version":"3.28.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-024-01120-9","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T16:13:36Z","timestamp":1731946416000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Third- or Further-Line Treatment in Patients with MSS Type Metastatic Colorectal Cancer"],"prefix":"10.1007","volume":"56","author":[{"given":"Miaomiao","family":"Gou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niansong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhikuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanghai","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"issue":"1","key":"1120_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"20","key":"1120_CR2","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909\u201319.","journal-title":"N Engl J Med"},{"issue":"9863","key":"1120_CR3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303\u201312.","journal-title":"Lancet"},{"issue":"6","key":"1120_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","volume":"16","author":"J Li","year":"2015","unstructured":"Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(6):619\u201329.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1120_CR5","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","volume":"36","author":"J Xu","year":"2018","unstructured":"Xu J, Kim TW, Shen L, et al. Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study. J Clin Oncol. 2018;36(4):350\u20138.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1120_CR6","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1200\/JCO.19.03296","volume":"38","author":"S Fukuoka","year":"2020","unstructured":"Fukuoka S, Hara H, Takahashi N, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol. 2020;38(18):2053\u201361.","journal-title":"J Clin Oncol"},{"key":"1120_CR7","doi-asserted-by":"crossref","unstructured":"Carlos A. Gomez-Roca EY, Seock-Ah Im ECA, H\u00e9l\u00e8ne Senellart MD, et al. LEAP-005: a phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors\u2014results from the colorectal cancer cohort. Journal of Clinical Oncology 2021 39:15_suppl, 3564\u20133564.","DOI":"10.1200\/JCO.2021.39.15_suppl.3564"},{"key":"1120_CR8","unstructured":"Marwan Fakih KPSR, David Z. Chang JCB, Timothy Larson ALC, et al. Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)\/microsatellite stable (MSS) colorectal cancer (CRC)."},{"key":"1120_CR9","doi-asserted-by":"publisher","unstructured":"F. Wang MH, Y. Yao ZW, Y. Jin FW, et al. A phase Ib\/II clinical trial of tolerability, safety and efficacy of regorafenib in combination with toripalimab (a PD-1 antibody) in patients with relapsed or metastatic colorectal cancer. Annals of Oncology (2020) 31 (suppl_4): S409-S461. https:\/\/doi.org\/10.1016\/annonc\/annonc270.","DOI":"10.1016\/annonc\/annonc270"},{"key":"1120_CR10","doi-asserted-by":"crossref","unstructured":"Miaomiao Gou HY, Liu Tie E ZW, Haiyan Si SC, Yuting Pan RF, Niansong Qian aGD. Fruquintinib combination with sintilimab in refractory metastatic colorectal cancer patients in China. Journal of Clinical Oncology 2020 38:15_suppl, 4028\u20134028. .","DOI":"10.1200\/JCO.2020.38.15_suppl.4028"},{"key":"1120_CR11","doi-asserted-by":"crossref","unstructured":"Ye Guo WZ, Jieer Ying YZ, Yueyin Pan WQ, et al. Preliminary results of a phase 1b study of fruquintinib plus sintilimab in advanced colorectal cancer. Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 2514\u20132514.","DOI":"10.1200\/JCO.2021.39.15_suppl.2514"},{"issue":"26","key":"1120_CR12","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509\u201320.","journal-title":"N Engl J Med"},{"key":"1120_CR13","doi-asserted-by":"crossref","unstructured":"Sophie Cousin CAB, Jean Philippe Gu\u00e9gan CAG, Jean-Philippe Metges AA, et al. REGOMUNE: a phase II study of regorafenib plus avelumab in solid tumors\u2014results of the non-MSI-H metastatic colorectal cancer (mCRC) cohort. Journal of Clinical Oncology 2020 38:15_suppl, 4019\u20134019.","DOI":"10.1200\/JCO.2020.38.15_suppl.4019"},{"key":"1120_CR14","doi-asserted-by":"publisher","unstructured":"Carlos Gomez-Roca EY, Seock-Ah Im ECA, Helene Senellart MD, et al. LEAP-005: a phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors\u2014results from the colorectal cancer cohort. Journal of Clinical Oncology 39, no. 3_suppl (January 20, 2021) 94\u201394.\u00a0https:\/\/doi.org\/10.1200\/JCO.2021.39.3_suppl.94.","DOI":"10.1200\/JCO.2021.39.3_suppl.94"},{"issue":"9","key":"1120_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100383","volume":"2","author":"F Wang","year":"2021","unstructured":"Wang F, He MM, Yao YC, et al. Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib\/II clinical trial and gut microbiome analysis. Cell Rep Med. 2021;2(9): 100383.","journal-title":"Cell Rep Med"},{"key":"1120_CR16","doi-asserted-by":"crossref","unstructured":"Richard D. Kim MT, Petr Kavan JC, Jeremy S. Kortmansky EXC, et al. Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI for metastatic colorectal cancer (CRC) in KEYNOTE-651: long-term follow-up of cohorts B and D. J Clin Oncol 40, 2022 (suppl 16; abstr 3521).","DOI":"10.1200\/JCO.2022.40.16_suppl.3521"},{"issue":"10","key":"1120_CR17","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1001\/jamaoncol.2021.2915","volume":"7","author":"E Martinelli","year":"2021","unstructured":"Martinelli E, Martini G, Famiglietti V, et al. Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. JAMA Oncol. 2021;7(10):1529\u201335.","journal-title":"JAMA Oncol"},{"key":"1120_CR18","doi-asserted-by":"crossref","unstructured":"Eric Xueyu Chen JML, Dongsheng Tu CJO, Hagen Fritz Kennecke DJJ, et al. Effects of liver metastases on efficacy of immune checkpoint blockade in treatment refractory, metastatic colorectal cancer (CRC): CCTG CO.26. Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 3600\u20133600.","DOI":"10.1200\/JCO.2022.40.16_suppl.3600"},{"issue":"6","key":"1120_CR19","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","volume":"20","author":"C Eng","year":"2019","unstructured":"Eng C, Kim TW, Bendell J, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019;20(6):849\u201361.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1120_CR20","doi-asserted-by":"publisher","first-page":"2120676","DOI":"10.1080\/2162402X.2022.2120676","volume":"11","author":"R Barnestein","year":"2022","unstructured":"Barnestein R, Galland L, Kalfeist L, Ghiringhelli F, Ladoire S, Limagne E. Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness. Oncoimmunology. 2022;11(1):2120676.","journal-title":"Oncoimmunology"},{"issue":"1","key":"1120_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","volume":"27","author":"J Yu","year":"2021","unstructured":"Yu J, Green MD, Li S, et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2021;27(1):152\u201364.","journal-title":"Nat Med"},{"key":"1120_CR22","doi-asserted-by":"crossref","unstructured":"Xu J, Kim TW, Shen L, et al. Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study. J Clin Oncol. 2017 : JCO2017743245.","DOI":"10.1200\/JCO.2017.74.3245"},{"issue":"24","key":"1120_CR23","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.2018.7855","volume":"319","author":"J Li","year":"2018","unstructured":"Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA. 2018;319(24):2486\u201396.","journal-title":"JAMA"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-024-01120-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-024-01120-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-024-01120-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T17:12:28Z","timestamp":1731949948000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-024-01120-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1120"],"URL":"https:\/\/doi.org\/10.1007\/s12029-024-01120-9","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"type":"print","value":"1941-6628"},{"type":"electronic","value":"1941-6636"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"assertion":[{"value":"29 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors had consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"This retrospective study was approved by the independent ethics committee of the Chinese PLA General Hospital and performed in accordance with the Declaration of Helsinki, and all the authors obtained written informed consent from the participants, to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"21"}}